Table 1.
Demographic and Clinical Characteristics of Cohort at Period 1 (n = 13,942)
| Variable | Number (%) |
|---|---|
| Gender | |
| Male | 9,841 (70.6%) |
| Female | 4,101 (29.4%) |
| Race/ethnicity | |
| White | 4,210 (30.2%) |
| Black | 6,489 (46.5%) |
| Hispanic | 3,059 (21.9%) |
| Other | 184 (1.3%) |
| HIV transmission risk | |
| MSM | 5,391 (38.7%) |
| IDU | 1,731 (12.4%) |
| Heterosexual | 4,290 (30.8%) |
| Heterosexual-IDU | 1,109 (7.9%) |
| MSM-IDU | 604 (4.3%) |
| Other | 374 (2.7%) |
| Missing | 443 (3.2%) |
| Age | |
| 18–34 | 3,056 (21.9%) |
| 35–49 | 8,558 (61.4%) |
| 50 and older | 2,328 (16.7%) |
| Lowest CD4 in period 1 | |
| ≤50 | 788 (5.7%) |
| 51≤CD4≤200 | 1,747 (12.5%) |
| 201≤CD4≤500 | 3,899 (28.0%) |
| >500 | 2,521 (18.1%) |
| No test reported | 4,987 (35.8%) |
| Insurance in period 1 | |
| Private | 1,391 (10.0%) |
| Medicaid | 4,766 (34.2%) |
| Medicare | 1,544 (11.1%) |
| Uninsured/Ryan White | 2,540 (18.2%) |
| Missing | 3,701 (26.6%) |
| HIV-1 RNA in period 1 | |
| >400 copies/ml | 5,396 (38.7%) |
| ≤400 copies/ml | 4,131 (29.6%) |
| No Test reported | 4,415 (31.7%) |
| HAART in period 1 | |
| No | 4,787 (34.3%) |
| Yes | 9,155 (65.7%) |
HAART, highly active antiretroviral therapy; IDU, injection drug use; MSM, men who had sex with men.